ID   NTRK2_HUMAN             Reviewed;         822 AA.
AC   Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=BDNF/NT-3 growth factors receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=GP145-TrkB;
DE            Short=Trk-B;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 2;
DE   AltName: Full=TrkB tyrosine kinase;
DE   AltName: Full=Tropomyosin-related kinase B;
DE   Flags: Precursor;
GN   Name=NTRK2; Synonyms=TRKB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB).
RC   TISSUE=Hippocampus;
RX   PubMed=7789988; DOI=10.1016/0888-7543(95)80055-Q;
RA   Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J.,
RA   Nycum L.M., Biegel J.A., Brodeur G.M.;
RT   "Cloning and chromosomal localization of the human TRK-B tyrosine
RT   kinase receptor gene (NTRK2).";
RL   Genomics 25:538-546(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1).
RC   TISSUE=Brain;
RX   PubMed=7823156;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Hippocampus;
RX   PubMed=7936202; DOI=10.1016/0306-4522(94)90507-X;
RA   Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M.,
RA   Colebrook S.M., Feeney R., Macgowan S.H.;
RT   "Cloning of a non-catalytic form of human trkB and distribution of
RT   messenger RNA for trkB in human brain.";
RL   Neuroscience 60:825-834(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND
RP   5), ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11798182; DOI=10.1006/bbrc.2001.6301;
RA   Stoilov P., Castren E., Stamm S.;
RT   "Analysis of the human TrkB gene genomic organization reveals novel
RT   TrkB isoforms, unusual gene length, and splicing mechanism.";
RL   Biochem. Biophys. Res. Commun. 290:1054-1065(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309.
RA   Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J.,
RA   Methner A.;
RT   "Full length truncated TrkB sequence identified in a screen for genes
RT   regulated by ischemic preconditioning.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121;
RP   ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412.
RX   PubMed=7574684; DOI=10.1006/abbi.1995.1460;
RA   Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.;
RT   "Extracellular domain of neurotrophin receptor trkB: disulfide
RT   structure, N-glycosylation sites, and ligand binding.";
RL   Arch. Biochem. Biophys. 322:256-264(1995).
RN   [12]
RP   INTERACTION WITH FRS2.
RX   PubMed=10092678; DOI=10.1074/jbc.274.14.9861;
RA   Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.;
RT   "The signaling adapter FRS-2 competes with Shc for binding to the
RT   nerve growth factor receptor TrkA. A model for discriminating
RT   proliferation and differentiation.";
RL   J. Biol. Chem. 274:9861-9870(1999).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1).
RX   PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x;
RA   Luberg K., Wong J., Weickert C.S., Timmusk T.;
RT   "Human TrkB gene: novel alternative transcripts, protein isoforms and
RT   expression pattern in the prefrontal cerebral cortex during postnatal
RT   development.";
RL   J. Neurochem. 113:952-964(2010).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 283-385.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M.,
RA   Reilly D., Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB
RT   and TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4.
RX   PubMed=11738045; DOI=10.1016/S0969-2126(01)00681-5;
RA   Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D.,
RA   Brady R.L.;
RT   "Specificity in Trk receptor:neurotrophin interactions: the crystal
RT   structure of TrkB-d5 in complex with neurotrophin-4/5.";
RL   Structure 9:1191-1199(2001).
RN   [17]
RP   VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706,
RP   FUNCTION AS A BDNF-ACTIVATED RECEPTOR, PHOSPHORYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15494731; DOI=10.1038/nn1336;
RA   Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J.,
RA   Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.;
RT   "A de novo mutation affecting human TrkB associated with severe
RT   obesity and developmental delay.";
RL   Nat. Neurosci. 7:1187-1189(2004).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] PHE-138.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [19]
RP   VARIANTS ILE-697; GLY-699 AND CYS-718.
RX   PubMed=18293376; DOI=10.1002/humu.20707;
RA   Marchetti A., Felicioni L., Pelosi G., Del Grammastro M.,
RA   Fumagalli C., Sciarrotta M., Malatesta S., Chella A., Barassi F.,
RA   Mucilli F., Camplese P., D'Antuono T., Sacco R., Buttitta F.;
RT   "Frequent mutations in the neurotrophic tyrosine receptor kinase gene
RT   family in large cell neuroendocrine carcinoma of the lung.";
RL   Hum. Mutat. 29:609-616(2008).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and the peripheral nervous systems
CC       through regulation of neuron survival, proliferation, migration,
CC       differentiation, and synapse formation and plasticity. Receptor
CC       for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-
CC       4. Alternatively can also bind NTF3/neurotrophin-3 which is less
CC       efficient in activating the receptor but regulates neuron survival
CC       through NTRK2. Upon ligand-binding, undergoes homodimerization,
CC       autophosphorylation and activation. Recruits, phosphorylates
CC       and/or activates several downstream effectors including SHC1,
CC       FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the
CC       GRB2-Ras-MAPK cascade that regulates for instance neuronal
CC       differentiation including neurite outgrowth. Through the same
CC       effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that
CC       mainly regulates growth and survival. Through PLCG1 and the
CC       downstream protein kinase C-regulated pathways controls synaptic
CC       plasticity. Thereby, plays a role in learning and memory by
CC       regulating both short term synaptic function and long-term
CC       potentiation. PLCG1 also leads to NF-Kappa-B activation and the
CC       transcription of genes involved in cell survival. Hence, it is
CC       able to suppress anoikis, the apoptosis resulting from loss of
CC       cell-matrix interactions. May also play a role in neutrophin-
CC       dependent calcium signaling in glial cells and mediate
CC       communication between neurons and glia.
CC       {ECO:0000269|PubMed:15494731}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: The neuronal activity and the influx of calcium
CC       positively regulate the kinase activity and the internalization of
CC       the receptor which are both important for active signaling.
CC       Regulated by NGFR that may control the internalization of the
CC       receptor. NGFR may also stimulate the activation by BDNF compared
CC       to NTF3 and NTF4. SH2D1A inhibits the autophosphorylation of the
CC       receptor, and alters the recruitment and activation of downstream
CC       effectors and signaling cascades. The formation of active
CC       receptors dimers able to fully transduce the ligand-mediated
CC       signal, may be negatively regulated by the formation of inactive
CC       heterodimers with the non-catalytic isoforms (By similarity).
CC       {ECO:0000250|UniProtKB:P15209, ECO:0000250|UniProtKB:Q63604}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Interacts
CC       (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1
CC       phosphorylation and activation. Interacts (phosphorylated upon
CC       activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1
CC       phosphorylation and activation. Interacts with SH2B1 and SH2B2.
CC       Interacts with NGFR; may regulate the ligand specificity of the
CC       receptor. Interacts (phosphorylated upon ligand-binding) with
CC       SH2D1A; regulates NTRK2. Interacts with SQSTM1 and KIDINS220 (By
CC       similarity). Interacts (phosphorylated upon ligand-binding) with
CC       FRS2; activates the MAPK signaling pathway. Interacts with APPL1
CC       (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P15209,
CC       ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:11738045}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P15209}. Endosome membrane
CC       {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P15209}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes
CC       upon ligand-binding. {ECO:0000250|UniProtKB:P15209}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=TrkB; Synonyms=gp145-TrkB;
CC         IsoId=Q16620-1; Sequence=Displayed;
CC       Name=TrkB-T1;
CC         IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902;
CC         Note=Non-catalytic isoform.;
CC       Name=TrkB-T-Shc;
CC         IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904;
CC       Name=4;
CC         IsoId=Q16620-4; Sequence=VSP_041942;
CC       Name=5;
CC         IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904;
CC       Name=TrkB-T-TK;
CC         IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179;
CC       Name=TrkB-N-T1;
CC         IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902;
CC   -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and
CC       peripheral nervous system. In the central nervous system (CNS),
CC       expression is observed in the cerebral cortex, hippocampus,
CC       thalamus, choroid plexus, granular layer of the cerebellum, brain
CC       stem, and spinal cord. In the peripheral nervous system, it is
CC       expressed in many cranial ganglia, the ophthalmic nerve, the
CC       vestibular system, multiple facial structures, the submaxillary
CC       glands, and dorsal root ganglia. Isoform TrkB-T1 is mainly
CC       expressed in the brain but also detected in other tissues
CC       including pancreas, kidney and heart. Isoform TrkB-T-Shc is
CC       predominantly expressed in the brain.
CC       {ECO:0000269|PubMed:11798182, ECO:0000269|PubMed:7936202}.
CC   -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain.
CC       {ECO:0000269|PubMed:7936202}.
CC   -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation
CC       that is required for interaction with SHC1 and PLCG1 and other
CC       downstream effectors. Isoform TrkB-T-Shc is not phosphorylated.
CC       {ECO:0000269|PubMed:15494731}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD)
CC       [MIM:613886]: A disorder characterized by early-onset obesity,
CC       hyperphagia, and severe developmental delay in motor function,
CC       speech, and language. {ECO:0000269|PubMed:15494731}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase
CC       since the first Trk was isolated as an oncogenic protein which was
CC       the result of a fusion between the tropomyosin gene TPM3 and
CC       NTRK1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NTRK2ID41589ch9q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U12140; AAC51371.1; -; mRNA.
DR   EMBL; S76473; AAB33109.1; -; mRNA.
DR   EMBL; S76474; AAB33110.1; -; mRNA.
DR   EMBL; X75958; CAA53571.1; -; mRNA.
DR   EMBL; AF410899; AAL67965.1; -; mRNA.
DR   EMBL; AF410900; AAL67966.1; -; mRNA.
DR   EMBL; AF410901; AAL67967.1; -; mRNA.
DR   EMBL; AF508964; AAM77876.1; -; mRNA.
DR   EMBL; AB209118; BAD92355.1; -; mRNA.
DR   EMBL; AK294285; BAG57570.1; -; mRNA.
DR   EMBL; AL445532; CAH71816.1; -; Genomic_DNA.
DR   EMBL; AL390777; CAH71816.1; JOINED; Genomic_DNA.
DR   EMBL; AL596132; CAH71816.1; JOINED; Genomic_DNA.
DR   EMBL; AL390777; CAH72193.1; -; Genomic_DNA.
DR   EMBL; AL596132; CAH72193.1; JOINED; Genomic_DNA.
DR   EMBL; AL390777; CAH72194.1; -; Genomic_DNA.
DR   EMBL; AL596132; CAH72194.1; JOINED; Genomic_DNA.
DR   EMBL; AL390777; CAH72195.1; -; Genomic_DNA.
DR   EMBL; AL445532; CAH72195.1; JOINED; Genomic_DNA.
DR   EMBL; AL596132; CAH72195.1; JOINED; Genomic_DNA.
DR   EMBL; AL596132; CAH72313.1; -; Genomic_DNA.
DR   EMBL; AL390777; CAH72313.1; JOINED; Genomic_DNA.
DR   EMBL; AL596132; CAH72314.1; -; Genomic_DNA.
DR   EMBL; AL390777; CAH72314.1; JOINED; Genomic_DNA.
DR   EMBL; AL596132; CAH72316.1; -; Genomic_DNA.
DR   EMBL; AL390777; CAH72316.1; JOINED; Genomic_DNA.
DR   EMBL; AL445532; CAH72316.1; JOINED; Genomic_DNA.
DR   EMBL; CH471089; EAW62688.1; -; Genomic_DNA.
DR   EMBL; BC031835; AAH31835.1; -; mRNA.
DR   CCDS; CCDS35050.1; -. [Q16620-1]
DR   CCDS; CCDS35051.1; -. [Q16620-5]
DR   CCDS; CCDS35052.1; -. [Q16620-3]
DR   CCDS; CCDS35053.1; -. [Q16620-2]
DR   CCDS; CCDS6671.1; -. [Q16620-4]
DR   PIR; A56853; A56853.
DR   PIR; I73631; I73631.
DR   RefSeq; NP_001007098.1; NM_001007097.2. [Q16620-2]
DR   RefSeq; NP_001018074.1; NM_001018064.2. [Q16620-1]
DR   RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5]
DR   RefSeq; NP_001018076.1; NM_001018066.2. [Q16620-3]
DR   RefSeq; NP_006171.2; NM_006180.4. [Q16620-4]
DR   RefSeq; XP_005252058.1; XM_005252001.2. [Q16620-4]
DR   RefSeq; XP_005252060.1; XM_005252003.2. [Q16620-4]
DR   RefSeq; XP_005252061.1; XM_005252004.2. [Q16620-4]
DR   RefSeq; XP_005252063.1; XM_005252006.3. [Q16620-5]
DR   RefSeq; XP_005252064.1; XM_005252007.3. [Q16620-2]
DR   RefSeq; XP_011517020.1; XM_011518718.2. [Q16620-1]
DR   RefSeq; XP_011517022.1; XM_011518720.2. [Q16620-3]
DR   RefSeq; XP_016870240.1; XM_017014751.1. [Q16620-4]
DR   RefSeq; XP_016870241.1; XM_017014752.1. [Q16620-1]
DR   RefSeq; XP_016870242.1; XM_017014753.1. [Q16620-1]
DR   RefSeq; XP_016870243.1; XM_017014754.1. [Q16620-1]
DR   RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5]
DR   RefSeq; XP_016870245.1; XM_017014756.1. [Q16620-5]
DR   RefSeq; XP_016870246.1; XM_017014757.1. [Q16620-3]
DR   RefSeq; XP_016870247.1; XM_017014758.1. [Q16620-2]
DR   RefSeq; XP_016870248.1; XM_017014759.1. [Q16620-2]
DR   RefSeq; XP_016870249.1; XM_017014760.1. [Q16620-2]
DR   RefSeq; XP_016870250.1; XM_017014761.1. [Q16620-2]
DR   UniGene; Hs.494312; -.
DR   UniGene; Hs.712776; -.
DR   PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383.
DR   PDB; 1WWB; X-ray; 2.10 A; X=283-385.
DR   PDB; 2MFQ; NMR; -; B=497-519.
DR   PDB; 4ASZ; X-ray; 1.70 A; A=527-822.
DR   PDB; 4AT3; X-ray; 1.77 A; A=527-822.
DR   PDB; 4AT4; X-ray; 2.36 A; A=527-822.
DR   PDB; 4AT5; X-ray; 1.71 A; A=527-822.
DR   PDBsum; 1HCF; -.
DR   PDBsum; 1WWB; -.
DR   PDBsum; 2MFQ; -.
DR   PDBsum; 4ASZ; -.
DR   PDBsum; 4AT3; -.
DR   PDBsum; 4AT4; -.
DR   PDBsum; 4AT5; -.
DR   ProteinModelPortal; Q16620; -.
DR   SMR; Q16620; -.
DR   BioGrid; 110970; 24.
DR   DIP; DIP-5720N; -.
DR   IntAct; Q16620; 8.
DR   MINT; MINT-156841; -.
DR   STRING; 9606.ENSP00000277120; -.
DR   BindingDB; Q16620; -.
DR   ChEMBL; CHEMBL4898; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   GuidetoPHARMACOLOGY; 1818; -.
DR   iPTMnet; Q16620; -.
DR   PhosphoSitePlus; Q16620; -.
DR   BioMuta; NTRK2; -.
DR   DMDM; 2497560; -.
DR   PaxDb; Q16620; -.
DR   PeptideAtlas; Q16620; -.
DR   PRIDE; Q16620; -.
DR   DNASU; 4915; -.
DR   Ensembl; ENST00000277120; ENSP00000277120; ENSG00000148053. [Q16620-4]
DR   Ensembl; ENST00000304053; ENSP00000306167; ENSG00000148053. [Q16620-5]
DR   Ensembl; ENST00000323115; ENSP00000314586; ENSG00000148053. [Q16620-1]
DR   Ensembl; ENST00000359847; ENSP00000352906; ENSG00000148053. [Q16620-2]
DR   Ensembl; ENST00000376208; ENSP00000365381; ENSG00000148053. [Q16620-3]
DR   Ensembl; ENST00000376213; ENSP00000365386; ENSG00000148053. [Q16620-1]
DR   Ensembl; ENST00000376214; ENSP00000365387; ENSG00000148053. [Q16620-4]
DR   Ensembl; ENST00000395882; ENSP00000379221; ENSG00000148053. [Q16620-2]
DR   GeneID; 4915; -.
DR   KEGG; hsa:4915; -.
DR   UCSC; uc004anz.1; human. [Q16620-1]
DR   CTD; 4915; -.
DR   DisGeNET; 4915; -.
DR   GeneCards; NTRK2; -.
DR   HGNC; HGNC:8032; NTRK2.
DR   HPA; HPA007637; -.
DR   MalaCards; NTRK2; -.
DR   MIM; 600456; gene.
DR   MIM; 613886; phenotype.
DR   neXtProt; NX_Q16620; -.
DR   OpenTargets; ENSG00000148053; -.
DR   Orphanet; 251612; Pilocytic astrocytoma.
DR   PharmGKB; PA31818; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   eggNOG; ENOG410YGKQ; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000264255; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; Q16620; -.
DR   KO; K04360; -.
DR   OMA; CSCEIMW; -.
DR   PhylomeDB; Q16620; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   SignaLink; Q16620; -.
DR   SIGNOR; Q16620; -.
DR   ChiTaRS; NTRK2; human.
DR   EvolutionaryTrace; Q16620; -.
DR   GeneWiki; TrkB_receptor; -.
DR   GenomeRNAi; 4915; -.
DR   PRO; PR:Q16620; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000148053; -.
DR   CleanEx; HS_NTRK2; -.
DR   ExpressionAtlas; Q16620; baseline and differential.
DR   Genevisible; Q16620; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB.
DR   GO; GO:0060175; F:brain-derived neurotrophic factor-activated receptor activity; IMP:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0007631; P:feeding behavior; IEA:Ensembl.
DR   GO; GO:0014047; P:glutamate secretion; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; ISS:UniProtKB.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 2.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR020455; Tyr_kin_neurotrophic_rcpt_2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF01462; LRRNT; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01941; NTKRECEPTOR2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Disease mutation; Disulfide bond; Endosome; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane;
KW   Neurogenesis; Nucleotide-binding; Obesity; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     31
FT   CHAIN        32    822       BDNF/NT-3 growth factors receptor.
FT                                /FTId=PRO_0000016727.
FT   TOPO_DOM     32    430       Extracellular. {ECO:0000255}.
FT   TRANSMEM    431    454       Helical. {ECO:0000255}.
FT   TOPO_DOM    455    822       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       32     61       LRRNT.
FT   REPEAT       92    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    196       LRRCT.
FT   DOMAIN      197    282       Ig-like C2-type 1.
FT   DOMAIN      295    365       Ig-like C2-type 2.
FT   DOMAIN      538    807       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     544    552       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    676    676       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     572    572       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        516    516       Interaction with SHC1. {ECO:0000250}.
FT   SITE        706    706       Interaction with SH2D1A. {ECO:0000250}.
FT   SITE        817    817       Interaction with PLCG1. {ECO:0000250}.
FT   MOD_RES     516    516       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     702    702       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     706    706       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     707    707       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     817    817       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:7574684}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    178    178       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    205    205       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    254    254       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   CARBOHYD    412    412       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7574684}.
FT   DISULFID     32     38       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:7574684}.
FT   DISULFID     36     45       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:7574684}.
FT   DISULFID    152    176       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:7574684}.
FT   DISULFID    154    194       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:7574684}.
FT   DISULFID    218    266       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:7574684}.
FT   DISULFID    302    345       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:7574684}.
FT   VAR_SEQ       1    156       Missing (in isoform TrkB-N-T1).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042177.
FT   VAR_SEQ     465    465       K -> KDFSWFGFGKVKSRQGV (in isoform 4 and
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:11798182}.
FT                                /FTId=VSP_041942.
FT   VAR_SEQ     467    477       PASVISNDDDS -> FVLFHKIPLDG (in isoform
FT                                TrkB-T1 and isoform TrkB-N-T1).
FT                                {ECO:0000303|PubMed:11798182,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7823156,
FT                                ECO:0000303|PubMed:7936202,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_002901.
FT   VAR_SEQ     478    822       Missing (in isoform TrkB-T1 and isoform
FT                                TrkB-N-T1). {ECO:0000303|PubMed:11798182,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7823156,
FT                                ECO:0000303|PubMed:7936202,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_002902.
FT   VAR_SEQ     529    537       FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-
FT                                T-Shc and isoform 5).
FT                                {ECO:0000303|PubMed:11798182}.
FT                                /FTId=VSP_002903.
FT   VAR_SEQ     538    822       Missing (in isoform TrkB-T-Shc and
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:11798182}.
FT                                /FTId=VSP_002904.
FT   VAR_SEQ     710    735       GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGP
FT                                LSLRDPCCICLLRLS (in isoform TrkB-T-TK).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_042178.
FT   VAR_SEQ     736    822       Missing (in isoform TrkB-T-TK).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_042179.
FT   VARIANT     138    138       L -> F (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041470.
FT   VARIANT     309    309       G -> R. {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_016320.
FT   VARIANT     338    338       N -> Y (in dbSNP:rs1047856).
FT                                /FTId=VAR_011973.
FT   VARIANT     545    545       G -> V (in dbSNP:rs1075108).
FT                                /FTId=VAR_049715.
FT   VARIANT     697    697       M -> I (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046518.
FT   VARIANT     699    699       R -> G (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046519.
FT   VARIANT     706    706       Y -> C (in OBHD; expressed normally on
FT                                the cell surface; results in markedly
FT                                impaired ligand-induced phosphorylation
FT                                as well as impaired downstream MAPK1
FT                                phosphorylation; dbSNP:rs121434633).
FT                                {ECO:0000269|PubMed:15494731}.
FT                                /FTId=VAR_065890.
FT   VARIANT     718    718       R -> C (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046520.
FT   STRAND      286    292       {ECO:0000244|PDB:1HCF}.
FT   STRAND      300    308       {ECO:0000244|PDB:1WWB}.
FT   STRAND      314    319       {ECO:0000244|PDB:1WWB}.
FT   STRAND      322    324       {ECO:0000244|PDB:1WWB}.
FT   STRAND      328    337       {ECO:0000244|PDB:1WWB}.
FT   STRAND      339    350       {ECO:0000244|PDB:1WWB}.
FT   HELIX       353    355       {ECO:0000244|PDB:1WWB}.
FT   STRAND      357    364       {ECO:0000244|PDB:1WWB}.
FT   STRAND      369    376       {ECO:0000244|PDB:1WWB}.
FT   STRAND      500    503       {ECO:0000244|PDB:2MFQ}.
FT   STRAND      506    512       {ECO:0000244|PDB:2MFQ}.
FT   TURN        515    517       {ECO:0000244|PDB:2MFQ}.
FT   HELIX       535    537       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      538    545       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      552    557       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      567    574       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       579    592       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      603    607       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      609    618       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       625    631       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       634    638       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      641    643       {ECO:0000244|PDB:4AT5}.
FT   HELIX       650    669       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       679    681       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      682    684       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       686    688       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      690    692       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       698    701       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       703    705       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      707    709       {ECO:0000244|PDB:4ASZ}.
FT   TURN        710    712       {ECO:0000244|PDB:4ASZ}.
FT   STRAND      713    715       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       717    719       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       722    727       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       732    747       {ECO:0000244|PDB:4ASZ}.
FT   TURN        748    750       {ECO:0000244|PDB:4ASZ}.
FT   TURN        753    756       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       759    768       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       780    789       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       794    796       {ECO:0000244|PDB:4ASZ}.
FT   HELIX       800    813       {ECO:0000244|PDB:4ASZ}.
SQ   SEQUENCE   822 AA;  91999 MW;  2FEB9159948F0D13 CRC64;
     MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP
     NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI
     NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES
     SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM
     NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH
     WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT
     LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST
     DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP
     LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL
     KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI
     VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI
     AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM
     PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ
     EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG
//
